EC ok’s US-made Covid-19 vaxx use in Europe; secures 160 mn doses

The European Commission has granted a conditional marketing authorisation (CMA) for Covid-19 vaccine Moderna, to be rolled out across the European Union. The authorisation is based upon the recommendation of the European Medicines Agency (EMA) for use of the Moderna vaccine for active immunisation to prevent Covid-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older.

The European Union, which is reportedly to have secured 160 million doses of  Moderna’s vaccine ,  is the fourth jurisdiction to authorise its use, after Israel earlier in January; and the US and Canada in December. Additional authorisations are currently under review  in Singapore, Switzerland, and the UK.

Meanwhile, the first deliveries of  the Moderna vaccines to European countries from its dedicated non-US supply chain are expected to begin next week.

Cambridge, Massachusetts-headquartered, Moderna currently has strategic alliances for development programmes with AstraZeneca and Merck & Co, Inc, as well as the Defence Advanced Research Projects Agency (DARPA), an agency of the US Department of Defense, and BARDA.

Category: Features, Pharmaceuticals